Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGreene King Share News (GNK)

  • There is currently no data for GNK

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TOP NEWS: Spire Healthcare Issues Profit Warning On Lower Admissions

Tue, 18th Sep 2018 08:59

LONDON (Alliance News) - Spire Healthcare Group PLC on Tuesday warned on its annual earnings outcome as it reported a drop in first half earnings due to falling admissions rates.

Shares in the FTSE 250-listed company were down 6.6% at 158.00 pence each, the worst performer on the FTSE 250 index.

The private healthcare operator also said that it has appointed John Forrest as chief operating officer, with effect on October 8. Forrest will be joining from fellow FTSE 250 constituent Greene King, where he is currently managing director for the Pub Partners division of the pub retailer, and has been for a year since 2017.

Forrest has been part of Greene King for nearly three years since 2015, and prior to that was part of blue chip hospitality firm Whitbread for nearly nine years from 2007 to 2015, leaving as chief operating officer for Premier Inn.

For the six months to the end of June, Spire reported pretax profit of GBP5.1 million, down sharply on GBP12.1 million the year before, on revenue that fell by 1.1% to GBP475.6 million from GBP481.0 million.

The fall in performance was due to lower in-patient and day case admissions, which dropped by 4.1% to 133,700 cases from 139,400, as well as a change in the admissions mix, with less orthopaedic work and more oncology.

There was also a decline in National Health Service admissions and revenue by 9.2%, which were hit by cost constraints and shift changes in referral management schemes.

Looking ahead, Spire expects earnings before interest, taxes, depreciation and amortisation for 2018 in the range of GBP120 million to GBP125 million, down from GBP150 million in 2017. Current trading in August has seen flat group revenue, with NHS revenue continuing to decline by a mid-single digit percentage, but growth in private payor revenue.

"We continue to review our non-clinical costs to ensure optimal efficiency. We have also robustly reviewed our previously proposed capital expenditure plans, and now expect to maintain the quality and capability of our asset base with a reduced level of expenditure. More broadly, the headwinds that Spire is facing, as the largest company in the sector by revenues and Ebitda, appear to be translating into significant business challenges for many sector participants, which in turn may lead to opportunities for Spire," said Chief Executive Officer Justin Ash.

"I believe our reset strategy is absolutely the right one for Spire and that Spire continues to be well positioned to reinforce its leading role in the independent sector and indeed in UK healthcare as a whole," Ash added.

Spire Healthcare declared an unchanged dividend of 1.3 pence per share for the first half.

More News
26 Aug 2015 12:40

Greene King's CFO and Sage Group's CEO buy stakes

(ShareCast News) - Greene King's chief financial officer Kirk Davis has bought 4,000 shares in the pub operator at 821p per share. Davis, previously finance director at JD Wetherspoon, became CFO of the company in October 2014. Shares were down 1.4% at 812.50p at 1522 BST on Wednesday. Meanwhile,

Read more
26 Aug 2015 09:05

DIRECTOR DEALINGS: Greene King CFO Buys First Shares

Read more
13 Aug 2015 05:13

Dividends Calendar - Week Ahead

Read more
12 Aug 2015 15:05

Dividends Calendar - Week Ahead

Read more
12 Aug 2015 05:12

Dividends Calendar - Week Ahead

Read more
11 Aug 2015 15:16

Dividends Calendar - Week Ahead

Read more
11 Aug 2015 05:14

Dividends Calendar - Week Ahead

Read more
10 Aug 2015 15:19

Dividends Calendar - Week Ahead

Read more
10 Aug 2015 05:20

Dividends Calendar - Week Ahead

Read more
7 Aug 2015 15:29

Dividends Calendar - Week Ahead

Read more
7 Aug 2015 05:12

Dividends Calendar - Week Ahead

Read more
6 Aug 2015 15:07

Dividends Calendar - Week Ahead

Read more
29 Jul 2015 18:33

Broker tips: Greene King, Hikma Pharmaceuticals

(ShareCast News) - Goldman Sachs reinstated its 'buy' rating on Greene King with a 1,060p price target, saying it expects the company to deliver consistent earnings growth given its exposure to accelerating UK consumer discretionary spending, execution of synergies post its Spirit acquisition and in

Read more
29 Jul 2015 14:48

Goldman Sachs reinstates Greene King at 'buy', sees consolidation driving margins

(ShareCast News) - Goldman Sachs reinstated its 'buy' rating on Greene King with a 1,060p price target, saying it expects the company to deliver consistent earnings growth given its exposure to accelerating UK consumer discretionary spending, execution of synergies post its Spirit acquisition and in

Read more
29 Jul 2015 08:37

BROKER RATINGS SUMMARY: Jefferies Upgrades Hikma To Buy From Hold

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.